pharma news today obesity glp-1 Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Dozens of new obesity drugs

A warm, firm response and a subject change are enough

Whether you're beginning treatment with Semaglutide Injection at $189/mo (or $149/mo on the 6-month plan) or exploring other compounds like Oral Semaglutide or Tirzepatide options, PlexusDx maintains flat monthly pricing across all commitment tiers, eliminating cost surprises as your treatment evolves

Warnings : If pregnant or breast-feeding do not use

& Panov, A

A new generation of oral tablets, multi-target agonists, and next-generation injectables is reshaping the competitive landscape at pace, with fresh regulatory approvals, pivotal Phase 3 data, and an expanding list of indications that stretches far beyond weight loss and type 2 diabetes

It also says that the plaintiffs expert witnesses are not qualified experts in causation and other facets of the litigation